Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Recare P2
- Development stage
- Unknown
- Lead developer
- Anglo-French Drugs & Industries
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Recare P2 is an oral joint and bone-health supplement developed and marketed by Anglo-French Drugs & Industries. Formulated as a tablet, it is indicated for the management of joint pain, bone-related disorders, and joint inflammation, including conditions such as osteoarthritis and rheumatoid arthritis. The supplement is reported to strengthen cartilage, provide elasticity and flexibility to the cartilage, support stronger joints, and reduce joint inflammation. Although its exact chemical composition is not publicly disclosed, it is registered as a pharmaceutical formulation and nutraceutical supplement to support overall bone and joint health.
- Brand names
- Recare P2
- Other names
- RECARE P2 Tablets
Beyond the preview
Go deeper on Recare P2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Recare P2.